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Abstract
Background: The mechanisms by which humans regulate pro- and anti-inflammatory responses on exposure to different
malaria parasites remains unclear. Although Plasmodium vivax usually causes a relatively benign disease, this parasite has
been suggested to elicit more host inflammation per parasitized red blood cell than P. falciparum.
Methodology/Principal Findings: We measured plasma concentrations of seven cytokines and two soluble tumor necrosis
factor (TNF)-a receptors, and evaluated clinical and laboratory outcomes, in Brazilians with acute uncomplicated infections
with P. vivax (n = 85), P. falciparum (n = 30), or both species (n = 12), and in 45 asymptomatic carriers of low-density P. vivax
infection. Symptomatic vivax malaria patients, compared to those infected with P. falciparum or both species, had more
intense paroxysms, but they had no clear association with a pro-inflammatory imbalance. To the contrary, these patients
had higher levels of the regulatory cytokine interleukin (IL)-10, which correlated positively with parasite density, and
elevated IL-10/TNF-a, IL-10/interferon (IFN)-c, IL-10/IL-6 and sTNFRII/TNF-a ratios, compared to falciparum or mixed-species
malaria patient groups. Vivax malaria patients had the highest levels of circulating soluble TNF-a receptor sTNFRII. Levels of
regulatory cytokines returned to normal values 28 days after P. vivax clearance following chemotherapy. Finally,
asymptomatic carriers of low P. vivax parasitemias had substantially lower levels of both inflammatory and regulatory
cytokines than did patients with clinical malaria due to either species.
Conclusions: Controlling fast-multiplying P. falciparum blood stages requires a strong inflammatory response to prevent
fulminant infections, while reducing inflammation-related tissue damage with early regulatory cytokine responses may be a
more cost-effective strategy in infections with the less virulent P. vivax parasite. The early induction of regulatory cytokines
may be a critical mechanism protecting vivax malaria patients from severe clinical complications.
Citation: Gonc¸alves RM, Scopel KKG, Bastos MS, Ferreira MU (2012) Cytokine Balance in Human Malaria: Does Plasmodium vivax Elicit More Inflammatory
Responses than Plasmodium falciparum? PLoS ONE 7(9): e44394. doi:10.1371/journal.pone.0044394
Editor: Georges Snounou, Universite´ Pierre et Marie Curie, France
Received February 14, 2012; Accepted August 6, 2012; Published September 4, 2012
Copyright:  2012 Gonc¸alves et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: RMG receives a scholarship from the Fundac¸a˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo (FAPESP) and MUF is a senior investigator supported by
the Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico (CNPq), Brazil. This work was supported by FAPESP (research grants 07/52771-0, 08/50645-0,
and 10/52146-0 to MUF) and CNPq (research grants 470195/2008-8 and 474529/2010-0 to MUF and KKGS). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: muferrei@usp.br
Introduction
Malaria is the most devastating protozoan disease afflicting
humans. Every year, Plasmodium falciparum causes around 0.5–3
million deaths, mostly in sub-Saharan Africa [1], while P. vivax, the
most widespread human malaria parasite [2], causes 130–390
million clinical episodes [3]. Although the pathophysiology of
vivax malaria remains poorly understood [4], adherence to
endothelial cells [5] and sequestration of infected red blood cells
in deep vasculature [6] have been recently demonstrated, while
severe vivax malaria is becoming increasingly common in South
and Southeast Asia, Oceania and South America [7,8].
Clearing malaria parasites without inducing major host
pathology requires a finely tuned balance between inflammatory
and regulatory cytokine responses, whose timing and magnitude is
crucial in determining malaria patient outcome [9]. Early
production of tumor necrosis factor (TNF)-a, interferon (IFN)-c,
interleukin (IL)-6, IL-12 and other inflammatory cytokines allows
fast P. falciparum clearance [10–12]. Once parasitemia is under
control, regulatory cytokines such as IL-10 and transforming
growth factor (TGF)-b are required to reduce the risk of severe
disease [13–15].
Cytokine responses have been extensively described in P.
falciparum infections in Africa and Oceania [12,15,16], but the
mechanisms by which semi-immune subjects regulate their
immune responses under low-level exposure to different malaria
parasite species remain obscure. Plasma concentrations of the
soluble TNF-a receptors sTNFRI and sTNFRII, which bind to
circulating TNF-a and regulate its activity, correlate positively
with parasitemia and disease severity in P. falciparum malaria in
Africa [17–19], but scant data are available for P. vivax infections
[20]. Although it has been suggested that P. vivax elicits greater
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host inflammation per parasitized red blood cell than P. falciparum
[21,22], we recently found a bias towards regulatory cytokines in
uncomplicated vivax malaria in Brazil [23]. It remains unclear
whether such a bias translates into milder clinical manifestations
and decreased risk of severe disease [24].
The present study investigated the cytokine interplay in relation
to the outcome of human malaria caused by P. vivax, P. falciparum
or both species. Cytokine responses and levels of soluble TNF-a
receptors were compared among malaria patients, asymptomatic
carriers of malaria parasites and apparently healthy controls
exposed to low-level malaria transmission in Brazil. To examine
whether cytokine responses correlated with parasitological and
clinical outcomes in P. vivax infections, parasitemias were estimated
by real-time polymerase chain reaction (PCR) and the intensity of
malaria-associated illness was quantified.
Methods
Study Participants
We recruited three groups of subjects exposed to hypoendemic
malaria transmission in northwestern Brazil: (a) symptomatic
malaria patients infected with P. vivax, P. falciparum or both species,
(b) asymptomatic carriers of low-density P. vivax infection, and (c)
healthy, non-infected controls. The symptomatic malaria patients
(127 patients aged 12–78 years) were enrolled from malaria clinics
in Pla´cido de Castro (Acre State) and Remansinho (Amazonas
State) [25,26]. They were infected with P. vivax (n = 85), P.
falciparum (n = 30), or both species (n = 12), and had a clinical
spectrum ranging from very mild illness to full-blown paroxysms
but included no severe or complicated malaria cases. Clinical and
laboratory data from 75 of these subjects had been previously
reported [23] and here are combined with additional laboratory
results from these same subjects and a complete analysis of an
additional 52 subjects living in the same areas. All patients were
treated free of charge in accordance with the current malaria
therapy guidelines in Brazil (see File S1: Methods online). Paired
blood samples were also collected from 39 P. vivax-infected patients
around 28 (range, 26–30) days after being started on antimalarial
chemotherapy, in order to evaluate cytokine levels during
convalescence. Levels of some cytokines in 22 of these paired
samples had been reported previously [23] and were combined
here with those for 17 additional pairs.
Samples from asymptomatic carriers of P. vivax infection were
collected from 45 subjects aged 4–56 years participating in an
ongoing prospective cohort study of malaria risk factors in the
farming settlement of Remansinho (Amazonas) [27]. These
subjects had very low P. vivax parasitemias detected by real-time
PCR, but were negative by thick smear microscopy; none of them
had fever or any malaria-related symptom up to seven days prior
to blood collection. Twenty apparently healthy subjects (aged 16–
69 years) living in the same areas, who were negative for malaria
parasites on both microscopy and real-time PCR, and had no
slide-confirmed malaria episode in the past six months, served as
malaria-exposed, non-infected controls. Demographic and clinical
characteristics of the study subjects are given in Table 1. This
study was approved by the Research Ethics Review Board of the
Institute of Biomedical Sciences of the University of Sa˜o Paulo,
Brazil (792/CEP). Written informed consent was obtained from all
study participants or their parents/guardians.
Measurement of Clinical Symptom Intensity
All patients were interviewed using a structured questionnaire
[28,29], regardless of the infecting parasite species, in order to
grade the intensity of 13 symptoms: fever, chills, sweating,
headache, myalgia, arthralgia, abdominal pain, nausea, vomiting,
dizziness, cough, dyspnea, and diarrhea. Clinical manifestations
were considered to be absent, mild, moderate or severe and were
assigned numerical scores of 0, 1, 2 or 3; fever was classified as
absent, mild or severe (0, 1 or 2), and vomiting and abdominal
pain were classified as either absent or present (0 or 1). To rank
subjects according to the overall intensity of malaria-associated
symptoms, numerical scores were aggregated into an index. We
used principal component analysis (PCA), carried out using the
XLSTAT software, version 7.5.2 (Addinsoft, New York, NY), to
derive weights assigned to each symptom [30]. PCA is a
multivariate statistical technique for summarizing the information
contained in a set of variables to a smaller number of dimensions
by creating a set of mutually orthogonal uncorrelated components
(the principal components). The first principal component explains
the largest possible variation in the data and can be used as a single
value that captures the information from a set of variables into one
composite measure. PCA was applied to variables (numerical
scores associated with each symptom), normalized by its mean and
standard deviation. The first principal component explained
27.7% of variability and gave the greatest weights to chills, fever,
sweating, nausea, headache, and dizziness. The normalized scores
assigned to each symptom were weighted using the PCA-derived
factor loadings and summed to give a clinical index for each
patient. The normalized scores were also used to build partial
indexes that included only symptoms associated with paroxysms
(fever, chills, and sweating) and body pains (myalgia, arthralgia,
and abdominal pain).
Clinical Laboratory Analysis
Blood cell counts and hemoglobin measurements were per-
formed using an ABX Micros 60 automated cell counter (Horiba,
Montpellier, France). Thick blood smears were stained with
Giemsa and at least 100 fields were examined under 10006
magnification (corresponding to an average of 0.1 ml of blood) for
malaria parasites by two experienced microscopists (see File S1,
Methods online). A quantitative real-time PCR method that
targets the 18S rRNA gene was standardized to estimate P. vivax
and P. falciparum parasitemias (see File S1, Methods online).
Parasitemia was expressed as the number of parasites per ml of
blood; in subjects co-infected with P. vivax and P. falciparum,
parasite counts for each species were summed to calculate total
parasitemias.
Cytokine and Soluble TNF-/ Receptor Measurements
Plasma samples were examined for TNF-/, IFN-c, IL-4, IL-10,
IL-12p40 and TGF-b using OptEIA capture ELISA kits (BD
Biosciences, San Jose´, CA), while levels of IL-6, sTNFRI and
sTNFRII were measured using DuoSet capture ELISA kits (R&D
Systems, Minneapolis, MN). Plasmas were tested in duplicate and
concentrations were expressed as pg/ml. IL-12 is a heterodimer
(known as IL-12p70) composed of two subunits, p35 and p40. The
p40 subunit of IL-12 is usually produced in higher amounts than
the bioactive p35 subunit and may act as a limiting factor for IL-
12p70 secretion. In addition, IL-12p40 acts as an antagonist of
human IL-12 receptor and inhibits IL-12-dependent immune
functions. For these reasons, IL-12p40 in this paper is regarded as
a regulatory or anti-inflammatory cytokine. Plasma levels of
TNF-/, IFN-c, IL-4, IL-10, IL-12p40 and TGF-b for 75 acute-
phase samples from symptomatic malaria patients and apparently
healthy controls and for 22 convalescence samples had been
previously reported [23] and here are combined with IL-6,
sTNFRI and sTNFRII measurements in these same samples and a
complete analysis in additional acute-phase and convalescence
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samples. To estimate the per-parasite production of cytokines and
soluble TNF-a receptors [21,22], measured concentrations (pg/
ml) were divided by parasite counts estimated using real-time PCR
(parasites/ml of blood); ratios are expressed as pg of cytokine per
103 parasites (TGF-b, sTNFRI and sTNFRII) or per 106 parasites
(all other cytokines).
Statistical Analysis
Cytokine levels with an overdispersed distribution were
summarized as medians and interquartile ranges and compared
across groups using nonparametric Kruskal-Wallis tests. When the
Kruskal-Wallis test indicated a significant difference (P,0.05)
among groups, pairwise Mann-Whitney U tests were carried out to
determine where differences lay. Paired data (acute-phase vs.
convalescence samples from the same patients) were compared
using Wilcoxon signed ranks tests. Correlations were assessed
using nonparametric Spearman rank correlation tests.
To determine whether independent variables (cytokine levels or
ratios and sTNFR levels) correlated with any of the four outcome
variables (hemoglobin levels, platelet counts, parasitemia, and
clinical index), a series of multiple linear regression models were
built. Given the relatively low number of subjects infected with
other species, this analysis was limited to subjects infected with P.
vivax for whom complete data were available. Parasitemias and
cytokine levels and ratios were log10-transformed toward normality
prior to analysis. Standardized regression coefficients (b) were
interpreted to indicate the influence of a given predictor
(independent variable) on each outcome (dependent variable),
controlling for all other independent variables in the model.
Separate regression models were built for each independent
variable and each outcome. The first models included age (years),
gender (female = 0, male = 1), and length of exposure to malaria
(years) as independent variables. Parasitemia was included as an
independent variable except when it was the outcome variable to
be analyzed. To determine whether correlations between the
outcome and particular cytokines (detected in partial models at 5%
level of significance) were independent of each other, a backward
stepwise approach was used to retain, in the final multiple linear
regression model, only those variables that remained correlated
with the outcome on the analysis after controlling for all other
predictors. Analyses were performed using SPSS 16.0 software
(SPSS, Chicago, IL), with statistical significance set at a 5% level.
Results
Characteristics of Study Subjects
Groups of symptomatic patients infected with P. vivax, P.
falciparum or co-infected with both species were comparable to
each other and to healthy control subjects in terms of age, gender,
length of exposure to malaria transmission (years of residence in
the Amazon), hemoglobin concentration, and anemia prevalence.
Asymptomatic P. vivax carriers, however, were younger and had
less cumulative exposure to malaria than the other study subjects
(Table 1). Parasite counts were low to moderate (range, 2.6 to
118750 [median, 765] parasites/ml of blood) among symptomatic
subjects and very low (range, 2 to 716 [median, 15.6] parasites/ml
of blood) among those with asymptomatic infection. Among
symptomatic patients, the highest and lowest geometric means
were found in P. vivax-only and mixed-species malaria, respectively
(P = 0.009 for this pairwise comparison, Mann-Whitney U test),
consistent with lower parasite counts reported in mixed-species
compared to single-species infections acquired in the same area
[31]. Median platelet counts were lower, with higher prevalence of
thrombocytopenia, in symptomatic P. vivax infections, compared to
symptomatic P. falciparum and mixed-species infections, as well as
to asymptomatic P. vivax infection.
Clinical Expression of Malaria
Clinical symptoms were analyzed for 84 laboratory-confirmed
single-species symptomatic infections with P. vivax, 27 single-
species infections with P. falciparum, and 11 mixed-species
infections with P. vivax and P. falciparum. Headache (91.8%), fever
(82.0%), chills (72.1%), sweating (63.1%), arthralgia (61.5%) and
myalgia (55.7%) were the most prevalent individual symptoms
(Figure 1), but typical paroxysm symptoms (fever, chills and
sweating) coexisted in only 64 (50.8%) subjects. Significant
differences across species were found, using sequentially Kruskal-
Wallis and Mann-Whitney tests, in the intensity of chills (greater in
vivax malaria than in falciparum malaria [P = 0.009] and mixed-
species malaria [P = 0.001]), sweating (greater in vivax than in
mixed-species malaria, P = 0.044) and dyspnea (greater in
falciparum than in vivax malaria, P = 0.005) (Figure 1).
Differences in the overall clinical index suggest that mixed-
species infections elicited milder symptoms, compared to single-
species infections with P. vivax or P. falciparum (Table 1), consistent
with intra-host between-species competition being beneficial to the
host [31]. Opposite effects of mixed-species infections, however,
have also been reported [32]. Paroxysms (quantified with partial
index) were more intense in vivax malaria than in single-species P.
falciparum and mixed-species infection (P = 0.028 and P = 0.003,
respectively, Mann-Whitney U tests), while falciparum malaria
patients had more intense body pain (myalgia, arthralgia, and
abdominal pain) than vivax malaria patients (P = 0.041, Mann-
Whitney U test).
Cytokines and Soluble TNF-/ Receptors during Malaria
Infection
Plasma concentrations of IL-4, IL-12p40, IFN-c, TNF-a, IL-10,
sTNFRI and sTNFRII were higher in one or more groups of
symptomatic patients, compared to non-infected controls (Table 2).
Although vivax malaria was associated with more intense
paroxysm-related symptoms, no pro-inflammatory imbalance
was found in these patients. In fact, this group had greater
concentrations of IL-10 (as described elsewhere [23,33,34]) and of
sTNFRII than patients infected with P. falciparum, and higher levels
of IL-10, IL-12p40, IFN-c, sTNFRI and sTNFRII than patients
infected with both species. Falciparum malaria was associated with
higher levels of circulating plasma TNF-a than mixed-species
infections.
Levels of cytokines or soluble TNF-a receptors often correlated
to each other in vivax malaria patients. For example, concentra-
tions of IL-10 correlated positively with those of IL-12p40
(rs = 0.452, P,0.0001), IFN-c (rs = 0.361, P = 0.001), IL-6
(rs = 0.439, P,0.0001), sTNFRI (rs = 0.449, P,0.0001) and
sTNFRII (rs = 0.395, P = 0.001). Levels of sTNFRI, but not those
of sTNFRII, correlated negatively with TNF-a concentrations
(rs =20.267, P = 0.038). Levels of both TNF-a receptors correlat-
ed positively with those of IL-6 (rs = 0.413 [P = 0.001] and
rs = 0.416 [P,0.0001] for sTNFRI and sTNFRII, respectively).
Among asymptomatic P. vivax carriers, concentrations of IL-10
correlated positively with those of IL-12p40 (rs = 0.459, P = 0.002),
IFN-c (rs = 0.516, P,0.001) and sTNFRII (rs = 0.429, P = 0.003);
no correlation was found between TNF-a or IL-6 concentrations
and levels of soluble TNF-a receptors.
To address the hypothesis that P. vivax elicits greater inflam-
matory cytokine response per parasitized red blood cell than other
human malaria parasites [21,22], we compared cytokine concen-
trations adjusted for parasitemias and found these comparisons to
Cytokines in vivax and falciparum Malaria
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be heavily influenced by differences in parasite density. We found
significantly higher per-parasite levels of TNF-a in mixed-species
symptomatic infections (median density, 228 parasites/ml) than in
single-species symptomatic P. vivax infections (median density,
1184 parasites/ml). However, the highest per-parasite levels of
cytokines and soluble TNF-a receptors were found among
asymptomatic carriers of very low P. vivax parasitemias (median
density, 16 parasites/ml), consistent with a non-linear relation
between parasite density and cytokine concentrations in vivax
malaria.
Because IL-10 regulates the production and function of
inflammatory cytokines [35], we computed IL-10/TNF-a, IL-
10/IFN-c and IL-10/IL-6 ratios and found a bias toward
regulatory cytokines in clinical vivax malaria (Table 2). Neverthe-
less, no clear anti-inflammatory bias could be observed among
asymptomatic carriers of P. vivax, who typically had low plasma
Figure 1. Severity of 13 malaria-associated symptoms in Amazonians with uncomplicated infection with Plasmodium vivax (A;
n=84), P. falciparum (B; n =27) or both species (C; n=11), diagnosed by thick-smear microscopy and confirmed by real-time PCR.
Symptoms are abbreviated as follows: fever = Fev; chills = Chi; sweating = Swe; headache = Hea; myalgia = Mya; arthralgia = Art; abdominal pain
= Abd; nausea = Nau; vomiting = Vom; dizziness = Diz; cough = Cou; dyspnea = Dys; diarrhea = Dia. Each bar segment represents the proportion
of subjects reporting a given symptom as absent (no shading), mild (light gray), moderate (dark gray) or severe (black).
doi:10.1371/journal.pone.0044394.g001
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concentrations of both inflammatory and regulatory cytokines
(Table 2).
Cytokines and Soluble TNF-a Receptors in Relation to
Clinical and Laboratory Outcomes during Plasmodium
vivax Infection
The relationships between levels of circulating cytokines during
acute malaria episodes (independent variables) and four outcomes
(dependent variables): hemoglobin levels, platelet counts, parasit-
emias, and symptom intensity, were then explored. Among 82
patients with clinical vivax malaria, age (b= 0.167, P = 0.005),
gender (b= 0.612, P,0.001) and parasitemia (b=20.231,
P = 0.009), but none of the cytokines or soluble TNF-a receptors,
were identified as independent predictors of hemoglobin levels in
vivax malaria in multiple linear models. Similar results have been
previously described in vivax malaria patients from Brazil [33] and
India [36]. The next model incorporated both symptomatic and
asymptomatic P. vivax infections (complete data for 109 subjects)
and yielded quite similar results: age (b= 0.190, P = 0.017), gender
(b= 0.528, P,0.001) and parasitemia (b=20.184, P = 0.021)
emerged as the only significant predictors of hemoglobin levels.
Next, we tested whether cytokines were associated with
thrombocytopenia, a common complication of P. vivax infections
in this (Table 1) and other studies [37,38]. Levels of the following
cytokines were negatively correlated with platelet counts on partial
linear regression models with data for symptomatic vivax malaria
infections: IL-12p40 (b=20.274, P = 0.014), IFN-c (b=20.254,
P = 0.020), IL-10 (b=20.310, P = 0.004), IL-10/TNF-a ratio
Table 2. Absolute and relative levels of cytokines in study participants.
Cytokine
Non-infected
controls
Symptomatic P. vivax
infection
Asymptomatic P. vivax
infection
Symptomatic P.
falciparum infection
Symptomatic mixed-
species infection P value
Number of subjects 18 81 45 30 12
IL-4 (pg/ml) 1.9 (1.7–2.5)a 3.9 (2.9–6.0)b 4.7 (4.1–5.8)c 3.4 (2.7–4.9)b 3.0 (2.4–3.7)b ,0.0001
IL-4 per parasite
(106)
- 4 (1–29)a 334 (54–840)b 5 (1–41)ac 20 (5–89)c ,0.0001
IL-12 (pg/ml) 30.8 (28.4–50.7)a 63.8 (42.8–94.3)b 53.1 (34.1–82.3)bc 53.2 (36.4–71.8)bc 39.7 (27.1–63.6)c 0.033
IL-12 per parasite
(106)
- 53 (11–405)a 3814 (575–7809)b 84 (10–1023)a 154 (41–1118)a ,0.0001
IFN-c (pg/ml) 5.4 (3.1–8.5)a 11.9 (5.5–36.8)b 4.0 (3.2–7.5)a 10.5 (4.4–61.3)b 3.8 (3.0–23.3)a ,0.0001
IFN-c per parasite
(106)
- 12 (1–96)a 344 (64–829)b 20.9 (6–240)a 40 (12–343)a ,0.0001
IL-6 (pg/ml) 10.3 (9.5–17.9) 13.4 (10.0–22.4) 11.1 (10.4–13.3) 13.2 (9.8–16.6) 10.2 (9.8–11.4) 0.177
IL-6 per parasite
(106)
- 15 (4–64)ac 898 (129–2869)b 26 (5–119)cd 64 (19–263)d ,0.0001
TNF-a (pg/ml) 3.8 (3.0–4.3)a 6.8 (4.9–9.8)bc 3.6 (3.1–5.0)a 7.8 (6.1–10.8)b 4.7 (3.2–9.7)ac ,0.0001
TNF-a per parasite
(106)
- 7 (2–35)a 299 (42–793)b 20 (12–119)ac 31 (12–118)c ,0.0001
IL-10 (pg/ml) 6.2 (4.4–9.1)a 260.1 (53.5–532.7)b 10.1 (8.0–16.8)c 47.8 (19.7–298.5)d 24.8 (5.5–121.3)cd ,0.0001
IL-10 per parasite
(106)
- 137 (39–731)a 815 (206–1899)b 78 (39–304)a 147 (74–265)a ,0.0001
TGF-b (pg/ml) 379 (178–1440)ab 948 (415–3862)c 368 (192–970)b 826 (492–1936)ac 720 (487–3802)c ,0.0001
TGF-b per parasite
(103)
- 1 (0.1–8)a 29 (6–86)b 2 (0.2–7)ac 11 (1–73)bc ,0.0001
sTNFRI (pg/ml) 648 (474–1728)ab 3015 (1487–5622)c 1097 (870–1377)a 2481 (855–4966)c 1127 (641–3385)ac ,0.0001
sTNFRI per parasite
(103)
- 3 (1–11)a 62 (23–211)b 4 (1–12)a 11 (3–20)a ,0.0001
sTNFRII (pg/ml) 3259 (2540–8016)a 16060 (10442–32971)b 4128 (3030–6704)a 10217 (6760–20598)c 7659 (4881–20479)c ,0.0001
sTNFRII per parasite
(103)
- 14 (3–63)ab 247 (52–809)c 24 (4–97)ad 63 (12–212)d ,0.0001
IL-10/TNF-a ratio 1.6 (1.3–1.9)a 39.3 (6.5–70.5)b 3.0 (2.0–4.3)c 6.0 (1.5–33.4)c 3.2 (1.7–13.7)c ,0.0001
IL-10/IFN-c ratio 1.4 (1.0–1.7)a 14.0 (3.2–39.3)b 2.5 (1.7–3.3)c 3.6 (1.5–9.7)c 3.5 (1.7–7.5)c ,0.0001
IL-10/IL-6 ratio 0.3 (0.2–0.5)a 9.6 (2.2–27.6)b 0.8 (0.6–1.5)c 3.9 (1.4–18.8)b 1.7 (0.5–9.6)c ,0.0001
sTNFRI/TNF-a ratio 619 (351–694) 405 (210–882) 281 (195–380) 306 (71.5–675) 188 (151–382) 0.066
sTNFRII/TNF-a ratio 2252 (1112–3639)ab 2902 (1284–5009)a 1004 (596–1766)b 1187 (539–2619)b 1681 (771–2514)ab ,0.0001
Plasma levels of TNF-/, IFN-c, IL-4, IL-10, IL-12 and TGF-b for 75 samples from symptomatic malaria patients and apparently healthy controls had been previously
reported [23] and here are combined with IL-6, sTNFRI and sTNFRII measurements in these same samples and a complete analysis of additional samples. Data are
expressed as median (interquartile range) unless stated otherwise and compared across three or four groups with Kruskal-Wallis tests (continuous variables) or x2 tests
(proportions); P values for this comparison across groups are presented in the right-hand column. When comparisons across groups showed statistical significance,
further pairwise comparisons were made using Mann-Whitney tests (continuous variables) or x2 tests (proportions). Values with different superscripts across a row
indicate pairwise comparisons with statistical significance at the 5% level. The same value may have more than one superscript. When pairs of values across a row share
one superscript (either the only or one of the superscripts associated with them), no statistically significant difference was found.
doi:10.1371/journal.pone.0044394.t002
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(b=20.321, P = 0.003) and sTNFRII (b=20.241, P = 0.034).
Regression models including IL-12p40, IFN-c, IL-10 or IL-10/
TNF-a ratio and sTNFRII as independent variables, in addition to
age, gender, length of exposure to malaria and parasitemia,
revealed that parasitemia (b=20.332, P = 0.005) and age
(b=20.419, P,0.001), but none of the other variables, were
independent predictors of platelet counts in vivax malaria. Only
age (b= 0.235, P = 0.014) remained as a significant independent
predictor of platelet counts in a multiple linear regression model
with all P. vivax-infected subjects with complete data (n = 109),
either symptomatic or not.
Although levels of several cytokines were proportional to
parasitemias in symptomatic vivax malaria, the direction of the
correlation varied. For instance, IL-4 (b=20.282, P = 0.007) and
TGF-b (b=20.303, P = 0.004) were negatively correlated, while
IL-10 (b= 0.297, P = 0.004) and sTNFRII (b= 0.259, P = 0.022)
levels and IL-10/TNF-a (b= 0.306, P = 0.002), IL-10/IFNc
(b= 0.388, P,0.0001) and sTNFRII/TNF-a ratios (b= 0.242,
P = 0.033) were positively correlated with parasite counts. Final
linear regression models that comprised IL-4, TGF-b, IL-10 or IL-
10/TNF-a or IL-10/IFNc ratio and sTNFRII or sTNFRII/TNF-
a ratio as independent variables, in addition to age, gender and
length of exposure to malaria, pointed to the length of exposure to
malaria (b=20.330, P = 0.002), TGF-b levels (b=20.323,
P = 0.003), and the IL-10/TNF-a ratio (b= 0.332, P = 0.004) as
major independent predictors of P. vivax parasitemias. Therefore,
anti-inflammatory cytokine levels may correlate either positively
(IL-10; as reported elsewhere [36,39,40]) or negatively (TGF-b) to
parasite density in uncomplicated but symptomatic vivax malaria.
A positive correlation was also found between sTNFRII levels and
parasite density in vivax malaria (b= 0.526, P = 0.015), consistent
with previous studies of P. falciparum infections in Africa [17,41,42].
Next we tested whether multiple linear models incorporating
asymptomatic carriers of low-level P. vivax parasitemia would yield
similar results (complete data for 127 subjects). We found that
plasma concentrations of sTNFRII (b= 0.361, P,0.001) and
either IL-10 levels (b= 0.503, P,0.001) or the ratios IL-10/TNF-
a (b= 0.324, P = 0.001) or IL-10/IFNc (b= 0.476, P,0.001)
correlated positively with parasite density in human infection with
P. vivax, regardless of the presence of symptoms.
No evidence was found suggesting that vivax malaria patients
tended to report milder clinical symptoms with increasing levels of
regulatory cytokines. To the contrary, IL-10 concentrations and
the IL-10/TNF-a ratio (b= 0.270, P = 0.014 and b= 0.225,
P = 0.046, respectively), in addition to levels of IL-6 (b= 0.302,
P = 0.014) and sTNFRII (b= 0.258, P = 0.035), were positively
correlated with the overall clinical index on partial multiple linear
regression models. The overall intensity of symptoms did not
correlate with patient age, length of residence in Amazonia, a
proxy of cumulative exposure to malaria, or with parasitemia.
Multiple regression models with IL-10 or IL-10/TNF-a ratio, IL-6
and sTNFRII failed to detect any independent correlation
between these cytokines and the overall clinical index because of
the clear co-linearity between many variables.
IL-10, IL-6 and sTNFRII levels (b= 0.308, P = 0.005,
b= 0.248, P = 0.043 and b= 0.273, P = 0.023, respectively) and
the IL-10/TNF-a ratio (b= 0.225, P = 0.046) were also correlated
with the intensity of paroxysm-related symptoms on partial
regression models. Similarly, multiple linear regression models
with IL-10 or IL-10/TNF-a ratio, IL-6 and sTNFRII were
affected by co-linearity between variables and failed to detect
independent predictors of paroxysm-related symptom intensity.
We conclude that a less inflammatory cytokine response in vivax
malaria did not translate into milder overall clinical manifestations
or less intense paroxysms.
Cytokines and Soluble TNF-a Receptors After Antimalarial
Chemotherapy
To examine whether levels of cytokines and soluble TNF-a
receptors remained elevated after parasite clearance following
chemotherapy, acute-phase and convalescence samples from P.
vivax malaria patients given standard chloroquine-primaquine
treatment were compared. No malaria parasites were detected by
real-time PCR in convalescence samples, and platelet counts had
returned to within the normal range after chemotherapy. Plasma
levels of IL-12p40, IL-6, IFN-c, IL-10, TGF-b, sTNFRI and
sTNFRII had decreased significantly, while those of IL-4 and
TNF-a remained stable during convalescence (Table 3), but were
elevated compared to non-infected controls (Table 1). The 40-fold
decrease in IL-10 levels in convalescence samples is particularly
noteworthy.
Discussion
In this study, we confirm early findings [23] of contrasting
patterns of cytokine balance in uncomplicated single-species
symptomatic infections with P. vivax and P. falciparum and in co-
infections with both species diagnosed in the same area of Brazil.
Contrary to the recent suggestion that P. vivax elicits more
inflammation than P. falciparum [21,22], we found higher IL-10/
TNF-a, IL-10/IFN-c and IL-10/IL-6 ratios, but similar inflam-
matory cytokine responses per parasitized red blood cell, in vivax
compared to falciparum malaria. IL-10/TNF-a ratio and
sTNFRII levels correlated positively with P. vivax parasitemia,
but not with symptom intensity. Furthermore, we showed that the
predominantly anti-inflammatory cytokine response in clinical
vivax malaria was short-lived, with IL-10 concentrations and IL-
10/TNF-a, IL-10/IFN-c and IL-10/IL-6 ratios all returning to
within the normal range found in non-infected controls after
chemotherapy.
Asymptomatic carriers of very low P. vivax parasitemias living in
the same region had substantially lower responses of both
inflammatory and regulatory cytokines than did patients with
clinical vivax malaria. They had higher levels of IL-4, IL-10 and
IL-12p40 than non-infected controls. Interestingly, asymptomatic
parasite carriers had the highest median IL-4 levels among all
groups of study subjects, either infected or not. Nevertheless, their
median IL-10 concentrations were more than 25-fold lower than
those found in symptomatic P. vivax infections. Concentrations of
sTNFRI and sTNFRII among asymptomatic carriers of P. vivax
were similar to those found among non-infected controls and 3 to
4-fold lower than those found in symptomatic P. vivax infections.
The finding of relatively low levels of most cytokines in
asymptomatic carriers of low-grade parasitemias suggests that a
parasite-density threshold must be reached before substantial
cytokine responses are triggered. In addition, we found no
evidence for an anti-inflammatory bias in the cytokine responses
of asymptomatic carriers of P. vivax.
We and others [33,34,40] have shown prominent IL-10
responses in symptomatic but uncomplicated P. vivax malaria,
but their main cellular sources remain largely unknown. Adaptive
type 1 regulatory (Tr1) CD4+ cells, which do not express CD25,
FoxP3 or CD127 on their surface, have recently been identified as
the main source of IL-10 in experimental murine infection with P.
yoelii [35]. However, in P. chabaudi infections in mice, activated
effector TH1 cells (IFN-c
+, ICOShigh, and CD127high) are major
producers of IL-10 [43]. Understanding how these non-classical
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regulatory cells are induced could help to explain species-related
differences in IL-10 production in human malaria.
Our cytokine measurements at a single time point are unable to
provide insights into the sequence of events from parasite
inoculation through the onset of clinical disease [11]. The
direction of some putative causal relationships is hard to infer.
For example, the positive correlation between IL-10 levels and P.
vivax density [39] and the detection of low plasma concentrations
of IL-10 in asymptomatic carriers of very low parasitemias
(Table 2) allow for two competing interpretations. High IL-10
levels may be a consequence of high parasite density if a minimum
density threshold is required to trigger substantial IL-10 produc-
tion. Alternatively, increased IL-10 levels may favor parasite
multiplication by inhibiting parasite-killing effector mechanisms in
humans [44] and mice [35].
Similarly, the findings of high levels of IL-4 among asymptom-
atic carriers of low parasite loads and a negative correlation
between IL-4 levels and parasitemias could be interpreted as
indicative that a strong IL-4 response helps to control P. vivax
parasitemias (and thus reduce the risk of malaria-related disease) at
the early stages of infection. Nevertheless, a single IL-4 measure-
ment during the course of infection does not allow us to infer a
causal relationship; alternatively, we may have simply detected
higher IL-4 levels in subjects that were enrolled at the early stages
of infection, while parasite densities are still low and disease is less
likely to occur.
The sharp increase in TNF-a levels preceding febrile paroxysms
in vivax malaria [45] can elicit the release of soluble TNF-a
receptors, which in turn regulate TNF-a activity. At low
concentrations, soluble TNF-a receptors, which are derived from
proteolytic cleavage of the cell-surface TNF-a receptor, stabilize
TNF-a and prolong its half-life [46]. At high concentrations,
however, they compete with TNF-a for binding with cellular
receptors, particularly membrane-bound TNF-a [47], thereby
inhibiting TNF-a bioactivity [48]. As a consequence, soluble TNF-
a receptors may be a more reliable biomarker of parasite-induced
inflammation than short-lived TNF-a and other classical pro-
inflammatory cytokines [49]. Since our vivax malaria patients
have higher sTNFRII concentrations (which correlate positively
with parasitemia) and sTNFRII/TNF-a ratios than falciparum
malaria patients, they have comparatively less free TNF-a
available for interaction with cell surface receptors.
Cytokine responses reflect different host strategies for control-
ling infection with different malaria species [50]. Controlling
virulent, fast-multiplying parasites such as P. falciparum blood stages
may require a double-edged strategy: a strong inflammatory
response that can prevent fulminant infections but which may lead
to severe disease. We hypothesize that tight control of parasite
growth is not required in vivax malaria, since parasites find a
limited supply of reticulocytes to parasitize in peripheral blood and
there is no risk of overwhelming parasitemias. As a consequence,
preventing inflammation-related tissue damage with an early
regulatory cytokine response may be the top priority, although this
strategy favors some parasite multiplication. Recent advances in
our understanding of the pathophysiology [4–6] and immunopa-
thology [24,51,52] of severe vivax malaria provide novel bases for
interpreting cytokine responses and their consequences in this
major human infection.
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